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    Type 2 diabetes mellitus（T2DM) is a risk factor of Alzheimer’s disease (AD), which is 
most likely linked to impairments of insulin signaling in the brain. Hence, drugs enhancing 
insulin signaling may have therapeutic potential for AD. Lixisenatide, a novel long-lasting 
glucagon-like peptide 1 (GLP-1) analogue, facilitates insulin signaling and has 
neuroprotective properties. We previously reported the protective effects of lixisenatide on 
memory formation and synaptic plasticity. Here, we describe additional key neuroprotective 
properties of lixisenatide and its possible molecular and cellular mechanisms against 
AD-related impairments in rats. The results show that lixisenatide effectively alleviated 
amyloid β protein (Aβ) 25-35-induced working memory impairment, reversed 
Aβ25-35-triggered cytotoxicity on hippocampal cell cultures, and prevented against 
Aβ25-35-induced suppression of the Akt-MEK1/2 signaling pathway. Lixisenatide also 
reduced the Aβ25-35 acute application induced intracellular calcium overload, which was 
abolished by U0126, a specific MEK1/2 inhibitor. These results further confirmed the 
neuroprotective and cytoprotective action of lixisenatide against Aβ-induced impairments, 
suggesting that the protective effects of lixisenatide may involve the activation of the 
Akt-MEK1/2 signaling pathway and the regulation of intracellular calcium homeostasis. 
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    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, afflicting more 
than 40 million people all around the world (World Alzheimer Report, 2015). It is 
characterized by memory loss and cognitive decline (Selkoe, 2001). One of the prominent 
events in the pathogenesis of AD is the formation of abundant deposits of senile plaques 
composed of amyloid β protein (Aβ) (Arnold et al., 1991; Thal et al., 2002). The toxicity of 
Aβ has been widely reported. For example, prolonged infusion of synthetic Aβ into the 
brain impaired learning and memory in rats, including working memory and place learning 
in the eight-arm radial maze, Y-maze and water maze (Nitta et al., 1997; Stepanichev et al., 
2005); Aβ destabilized neuronal calcium homeostasis, altered cellular ionic activity, and 
rendered neurons more vulnerable to toxic stimuli in human cerebral cortical cell cultures 
(Fraser et al., 1997; LaFerla, 2002); Aβ acutely impaired synaptic functions when added to 
hippocampal slices or slice cultures (Li et al., 2009). Not only full length Aβ but also its 
fragments, such as Aβ25-35 and Aβ31-35, could induce apoptosis in cultured cortical 
neurons (Yan et al., 1999), in vivo LTP (Gault and Holscher, 2008), and cognitive deficits 
in rats (Alkam et al., 2007; Yuan et al., 2016). Unfortunately, effective neuroprotective 
strategies against Aβ neurotoxicity are still lacking. 
    Epidemiological studies found a clear correlation between type 2 diabetes mellitus 
(T2DM) and AD, in which T2DM has been identified as a risk factor for AD and the insulin 
resistance in the brain might initiate or accelerate the development of AD (Luchsinger et al., 
2004; Ohara et al., 2011; Talbot et al., 2012). Based on these observations, it might be a 
promising strategy to normalize insulin signaling in the brain for the prevention and 
treatment of AD. Glucagon-like peptide 1 (GLP-1), an incretin hormone, and GLP-1 
analogues that are protease resistant, have been reported to be able to cross the blood-brain 
barrier (BBB) and it facilitates insulin signaling (Gengler et al., 2012; Holscher, 2014a; 
Hunter and Holscher, 2012a). Furthermore, it has been found that GLP-1 and the GLP-1 
receptor (GLP-1R) are expressed in the rodent central nervous system (Cork et al., 2015; 
Merchenthaler et al., 1999), especially the memory-related brain regions, such as the 
hippocampus (Cork et al., 2015; During et al., 2003; Hamilton and Holscher, 2009). More 
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importantly, GLP-1 possesses neurotrophic properties (Holscher, 2014b; Perry et al., 2002b), 
and could protect neurons against glutamate-induced apoptosis and even decrease 
endogenous Aβ accumulation in cellular and animal models of AD (Li et al., 2010; 
McClean et al., 2011b). However, endogenous GLP-1 is broken down quickly and lasts for 
only several minutes in blood plasma, which greatly limits its application in clinical practice 
(Deacon et al., 1995). Currently, several GLP-1 mimetics are on the market (e.g. exendin-4 
(Byeatta), liraglutide (Victoza) and lixisenatide (Lyxumia)). They have been engineered and 
developed to resist protease degradation (Christensen et al., 2011; Holst, 2004; Madsbad et 
al., 2008; Vilsboll, 2009). These GLP-1R agonists enhance cognition and reduce blood 
glucose levels in T2DM models (Gumuslu et al., 2016), but do not affect blood glucose 
levels in non-diabetic animals or people (McClean and Holscher, 2014). It has been 
reported that exendin-4 enhanced nerve growth factor (NGF)-induced cell differentiation 
into neurons (Perry et al., 2002a), and showed pronounced neuroprotective and 
anti-inflammatory effects in middle-aged diabetic animals (Darsalia et al., 2012), reversed 
T2DM-induced neuronal pathology in the piriform cortex of the rat (Lietzau et al., 2016), 
and antagonized Aβ1-42-induced suppression of hippocampal long-term potentiation in rats 
(Wang et al., 2015). Liraglutide also enhanced synaptic plasticity in the hippocampus of the 
APP/PS1 AD mouse model (McClean et al., 2010), reduced the chronic inflammation 
response (McClean et al., 2011a; Parthsarathy and Holscher, 2013), and ameliorated 
working memory impairment in the Aβ-induced AD mouse model (Qi et al., 2016). 
Lixisenatide, a novel long-lasting GLP-1 analogue, has a higher permeability across the 
BBB and greater biological activity than exendin-4 and liraglutide (Hunter and Holscher, 
2012b; Liu et al., 2015). Our previous studies (Cai et al., 2014) showed that lixisenatide 
prevented Aβ25-35 -induced spatial memory deficits and hippocampal LTP suppression in 
rats. In the present study, we first observed the effects of lixisenatide on Aβ-induced deficits 
in spatial working memory of rats and cultured cell viability by using Y maze test and 
primary hippocampal neuronal cultures. Furthermore, the molecular and cellular 
mechanisms underlying the neuroprotective role of lixisenatide were investigated by using 
the Western blotting technique and intracellular calcium imaging. 





2.1 Animals and drugs 
Adult male Sprague Dawley (SD) rats (200–230 g) were provided by the Animal 
Research Center of Shanxi Medical University. All animal handling and procedures 
accorded with the guidelines of the Shanxi Animal Research Ethics Committee. During 
experiments, rats were kept at controlled room temperature (20–24°C) and humidity (60%–
80%). Aβ25–35 and lixisenatide (Sigma, St. Louis, MO, USA) were stored in dry form and 
dissolved in saline (5 nmol/µl) before experiments. 
 
2.2 Intrahippocampal injection 
    Intrahippocampal injection was performed as previously described (Ryu and 
McLarnon, 2006, 2008). In brief, SD rats were anesthetized (chloral hydrate, 0.3 g/kg, i.p.) 
and placed in a stereotaxic apparatus (Narishige, Tokyo, Japan). Lixisenatide (5 nmol/µl) or 
vehicle (0.9% NaCl) and Aβ25–35 (5 nmol/µl) or saline (0.9% NaCl) were bilaterally 
injected into the hippocampi (anterior-posterior: -3.0 mm; medial-lateral: ±2.2 mm; 
dorso-ventral: -3.0 mm, from bregma), with an injection rate of 0.2 µl/min under the control 
of a micropump (KD Scientiﬁc, Inc, KDS310 Plus, USA). In co-application group, 
lixisenatide was injected 15 min before Aβ25–35 application. To make sure the drugs were 
fully dispersed into the hippocampus, a 5 min-retention of the injection syringe in the brain 
was given after every injection.  
 
2. 3 Y maze test 
Spontaneous alternation of Y maze was performed to examine the spatial working 
memory of rats. Rats were examined 10 days after drug administration. The Y maze has 
three redial arms (A, B, C) with the same angle (120º) between arms. Each arm is 45 cm 
long and 12 cm high. Rats were put into the junction of three arms and allowed to move 
freely for 8 min session. The entries of rats into each arm were recorded and every entry 
different from last two entries was considered as a successful alternation. The alternation 
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percentage was calculated according to the following: [(number of alternations)/(total 
number of arm entries－2)] × 100(%) (Iwai et al., 2014). 
 
2.4 Primary hippocampal neuronal cell culture 
Primary hippocampal formation cultures were prepared from 24 hours postnatal SD 
rats. Briefly, pups were anesthetized with ether, and sterilized in 75% ethanol. Rat brains 
were quickly removed into ice-cold dissection solution. The hippocampi were stripped and 
cut into small pieces (each cube <1 mm3). The tissue pieces were incubated with 0.125% 
trypsin at 37℃ for 15-20 min, and then complete culture medium was added to stop 
enzymatic reaction. Single-cell suspensions were obtained by mechanical dissociation using 
a Pasteur pipette with a fire-polished tip in complete culture medium, and then filtered 
through a 200 mesh nylon screen, centrifuged for 5 min at 1000 rpm. The cells at the 
bottom were resuspended with fresh complete culture medium and plated on poly-D-lysine 
coated 96-well plates and 35 mm culture dishes (Corning Inc) at a density of 5×105 cells/ml. 
Cultures were maintained in 5% CO2 at 37℃in complete culture medium for 6 h. The 
culture media were then changed to serum-free B27/neurobasal medium. Afterward, half of 
the culture medium was replaced with fresh serum-free B27/neurobasal medium every 3 
days. 7-10 days after plating, the mature cells were used for further experimental 
observation. The experiment was all carried out under sterile condition. 
 
2.5 Cell viability assay 
To assess the rate of cell viability, cell counting kit-8 (CCK-8) and lactate 
dehydrogenase (LDH) were used. Briefly, cells were inoculated in 96-well plates. After 
7-10 days, cells were incubated with Aβ25–35 (10 µM) for 24 hours. In co-application 
group, Lixisenatide (100 µM) were applied 24 hours before Aβ25–35 treatment. Six wells 
were used for each sample, and each experiment was repeated three times. CCK-8 solution 
(10 µl) was added to each well, then cells were incubated at 37℃ for 2 h. The absorbance 
of samples was measured by a microplate reader (SpectraMAX 190, Molecular Devices, 
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Sunnyvale, CA) at 450 nm. Supernatant was collected to measure the LDH (a stable 
cytosolic enzyme, which is released upon cell lysis) release according to the manufacturer’s 
instructions. 
 
2.6 Western blotting 
Cell lysate containing 5 µg of protein was separated on 4–12% gel and electrophoresed 
in running buffer at 200 mV for 35 min, followed by transfer to polyvinylidenedifluoride 
membrane. The membrane was washed in 1X TBST and blocked in 5% skimmed milk for 2 
h at 25℃ . The membrane was then incubated with anti-pAkt (Ser473) (1:400) and 
anti-phospho-MEK1/2 (Ser217/221) (1:1000) antibodies at 4℃ overnight. All the primary 
antibodies used were generated in rabbit. β-actin was used as loading control. The 
membrane was incubated with 1:400 horseradish peroxidase-conjugated anti-rabbit IgG for 
2 h at 25℃. Relative density of bands was calculated. 
 
2.7 Confocal calcium imaging   
Intracellular free Ca2+ was measured with fluorescent dye Fluo-3/AM utilizing 
confocal laser scanning microscope (CLSM) (Olympus, FV-1000). Briefly, cultures were 
washed three times with balanced salt solution. Then, cells were loaded with the same 
solution containing 5 µM fluorescent Ca2+ indicator dye Fluo-3/AM for 1 h in a dark place 
at 37℃. To remove the extracellular Fluo-3/AM, the loaded cells were rinsed three times 
with the balanced salt solution. Live video calcium images of selected neurons under 
microscopic field were recorded with a CLSM. Excitation wavelength of 488 nm and 
emission wave length of 526 nm were selected for the Fluo-3/AM fluorescence. Images 
were typically collected at 10-sec interval and recorded at least 20 min. The fluorescence 
intensities associated with a given cell were determined from digitized images and the data 
were processed using Olympus image analysis software. The experiment was carried out in 
the dark. 




2.8 Data analysis 
    All values in the experiments were expressed as means ± standard errors (SEM). The 
SPSS 13.0 and SigmaPlot 11.0 statistical packages were used for statistical analyses. The 
data from Y maze test, cell viability assay and western blotting were examined by a 
two-way repeated measures analysis of variance (ANOVA). The data from confocal 
calcium imaging was performed by using one-way ANOVA and Student-t test. The 
statistical significance level was defined as p < 0.05. 
 
3. Results 
3.1 Lixisenatide reversed the Aβ25-35-induced impairment of spatial working memory 
Two-way ANOVA showed Aβ25-35 injection and lixisenatide pretreatment had 
significant main effects on the spontaneous alternation of rats (Aβ25-35: F (1,36)＝139.156, 
P<0.001; lixisenatide: F (1,36)＝137.718, P<0.001; Aβ25-35 by lixisenatide: F (1,36)＝
163.483, P<0.001). As shown in the Figure 1A, Tukey’s post hoc tests showed that 
Aβ25-35 significantly reduced the percentage of right turns of rats (P<0.001, n=10) and 
lixisenatide reversed this detrimental effect (P<0.001, n=10). At the same time, the total 
arm entries of rats did not show any significant difference among these groups (P>0.05; 
Figure 1B). 
 
3.2 Lixisenatide inhibited the Aβ25-35-induced cytotoxicity on cultured hippocampal 
cells  
Two-way ANOVA showed Aβ25-35 injection and lixisenatide pretreatment had 
significant main effects on the viability of cultured hippocampal formation by CCK-8 assay 
(Aβ25-35: F (1,36)＝ 382.892, P<0.001; lixisenatide: F (1,36)＝ 180.696, P<0.001; 
Aβ25-35 by lixisenatide: F (1,36)＝203.032, P<0.001). As shown in the Figure 2A, 
Tukey’s post hoc tests showed that Aβ25-35 significantly decreased the viability of 
hippocampal formation cultures (P<0.001, n=10) and lixisenatide reversed this toxicity 
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effect (P<0.001, n=10). Two-way ANOVA showed Aβ25-35 injection and lixisenatide 
pretreatment had significant toxic effects on the viability of cultured hippocampal formation 
by LDH assay (Aβ25-35: F (1,36)＝330.942, P<0.001; lixisenatide: F (1,36)＝183.66, 
P<0.001; Aβ25-35 by lixisenatide: F (1,36)＝111.299, P<0.001). As shown in the Figure 
2B, Tukey’s post hoc tests showed that Aβ25-35 significantly induced the death of cultured 
hippocampal formation (P<0.001, n=10) and lixisenatide weakened this bad effect (P<0.001, 
n=10).  
 
3.3 Lixisenatide  relieved the Aβ25-35-induced suppression of the Akt-MEK1/2 
signaling pathway 
The neuroprotection of lixisenatide might be related to the Akt-MEK1/2 signal 
pathway. Two-way ANOVA showed Aβ25-35 injection and lixisenatide pretreatment had 
significant main effects on the level of pAkt (Aβ25-35: F (1,36)＝6.984, P<0.05; 
lixisenatide: F (1,36)＝8.492, P<0.05; Aβ25-35 by lixisenatide: F (1,36)＝9.398, P<0.05). 
As shown in the Figure 3A, Tukey’s post hoc tests showed that Aβ25-35 significantly 
decreased the level of pAkt (P<0.05, n=10) and lixisenatide reversed this decrease (P<0.05, 
n=10). Two-way ANOVA showed Aβ25-35 injection and lixisenatide pretreatment had 
significant main effects on the level of pMEK1/2  (Aβ25-35: F (1,36)＝7.429, P<0.05; 
lixisenatide: F (1,36)＝4.499, P<0.05; Aβ25-35 by lixisenatide: F (1,36)＝5.409, P<0.05). 
As shown in the Figure 3B, Tukey’s post hoc tests showed that Aβ25-35 induced a 
significant decrease in the level of MEK1/2 (P<0.05, n=10) and this decrease was reversed 
by lixisenatide (P<0.05, n=10). 
 
3.4 Lixisenatide significantly protected against the Aβ25-35-induced elevation of 
[Ca2+]i , which was abolished by a MEK1/2 inhibitor 
The cell mechanism of Aβ-induced neurotoxicity involves in the perturbation of Ca2+ 
homeostasis. Firstly, we investigated the change of [Ca2+]i level in rat primary cultured 
hippocampal neuron by applying 10 µM Aβ25-35. As shown in the Figure 4B, the relative 
fluorescent intensity at resting condition in the control group (n=20) was very stable, nearly 
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showing as a straight horizontal line. After application of Aβ25-35 (n=20), the fluorescent 
intensity in most of neurons gradually and persistently increased during all of recording 
time. Figure 4C showed the relative fluorescent intensity values of [Ca2+]i in different 
experimental groups at 20 min after application of Aβ25-35. Obviously, Aβ25-35 increased 
the relative fluorescent intensity of [Ca2+]i, being 185.34± 3.2%, significantly higher than 
the value in the control group (P<0.01). This result indicated that Aβ25-35 could increase 
[Ca2+]i, which might contribute to the neurotoxicity of Aβ seen in cultured hippocampal 
neurons. Further, we investigated the pretreatment effect of lixisenatide on Aβ25-35 
induced [Ca2+]i elevation. As shown in the Figure 4C, Aβ25-35-induced elevation of [Ca2+]i 
level was mostly reversed by lixisenatide (100 µM) and the relative fluorescent intensity 
decreased to 134.01 ± 2.7% (n=20, P<0.01). These results indicated that lixisenatide could 
protect against Aβ25-35-induced intracellular calcium overloading.  
To investigate the molecular mechanism of the protection of lixisenatide against 
Aβ25-35, we also observed the effect of lixisenatide on Aβ25-35-induced [Ca2+]i elevation 
in the presence of U0126, a MEK1/2 inhibitor. The result showed that treatment with 
U0126 for 20 min, essentially blocked the protective effect of lixisenatide against Aβ25-35 
induced [Ca2+]i elevation. Compared with co-application of lixisenatide and Aβ25-35, the 
relative fluorescent intensity in co-application of U0126 (1 mM), lixisenatide (100 µM) plus 
Aβ25-35 group increased to 166.18 ± 3.1% (n=20, P<0.01).These results indicated that the 
protective role of lixisenatide against Aβ25-35 induced [Ca2+]i elevation might be closely 
associated with the activation of MEK1/2. 
 
4. Discussion 
AD is a biologically complex neurodegenerative syndrome. Nearly 20 years ago, with 
the combination of observations from biochemistry, neuropathology and genetics, a 
compelling hypothesis known as the amyloid cascade hypothesis was formulated. Although 
growing amounts of data are inconsistent with the basically linear causal chain of events of 
this hypothesis (Herrup, 2015), it has been recognized that Aβ plays a key part in the early 
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development of the pathogenesis of AD. The amyloid plaque load does not correlate with 
disease progression at a later stage of disease (Edison et al., 2008). The neurotoxicity of 
different Aβ fragments such as Aβ1-42 and Aβ1-40 was observed in cell culture first. Aβ 
peptide- induced cell apoptosis and death in cultured cortical neurons is a common 
observation (Deshpande et al., 2006). The sequence 25-35 of Aβ is further recognized as an 
active site of Aβ, as this fragment shows similar neurotoxic properties to the full length of 
Aβ (Holscher et al., 2007). Aβ25-35 can induce cell apoptosis and necrosis in cultured 
hippocampal neurons (Sendrowski et al., 2015).	Therefore, the present study used Aβ25-35 
in primary cell culture and behavioral experiments. For the cell viability assay, mature 
neurons were exposed to Aβ25–35 for 24 hours. For behavioral memory testing, a Y maze 
test was performed. The injected solution includes soluble monomers, dimers, and 
oligomers. It has been proposed that soluble oligomeric forms of Aβ were the chief 
mediators of cytotoxicity in AD (Ashe and Aguzzi, 2013; Selkoe, 2002; Wisniewski and 
Goni, 2015). Other configurations of amyloid also can induce neuronal death (Orellana et 
al., 2011). GLP-1 is an incretin hormone which effectively re-sensitizes insulin signaling 
and physiological activity by increased expression of the insulin receptor gene (Doyle and 
Egan, 2007). Another benefit for using GLP-1 in AD treatment is that GLP-1 does not 
affect blood glucose level in normoglycemic people (Gallwitz, 2006; Vella et al., 2002). 
However, natural GLP-1 lasts only several minutes in blood plasma because of 
DPP4-induced degradation (Deacon et al., 1995). Fortunately, many GLP-1 analogues with 
longer half-life, such as lixisenatide used in the present study, have been developed and 
even applied to clinical treatment (Elkinson and Keating, 2013; Holst, 2004; Shyangdan et 
al., 2011).  
Memory dysfunction is a prominent symptom of patients with AD (Webster et al., 
2014). Spontaneous alternation test of rats with Y maze is a hippocampal dependent 
short-term spatial working memory (Stuchlik et al., 2014). In the present study, our 
behavioral results show that bilateral intrahippocampal injection of Aβ25-35 significantly 
decrease the percentage of alternation of rats, and lixisenatide reversed this detrimental 
effect. At the same time, the total arm entries of rats did not show any significant 
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differences among these groups, suggesting the difference in spontaneous alternation among 
these groups was due to the change in spatial working memory, but not impairing general 
locomotor activity of rats.  
    In cell culture and cell viability experiments, we found that the cell viability of 
hippocampal cell cultures significantly decreased in Aβ25-35 alone group, which is 
consistent with the behavioral results in the Y maze test. Interestingly, lixisenatide inhibited 
Aβ25-35-induced cytotoxicity, with a significant viability recovery in the lixisenatide plus 
Aβ25-35 group, compared with Aβ25-35 only group. The Akt-MEK1/2 signaling pathway 
is important for cell survival (Wang et al., 2010). The suppression of the Akt-MEK1/2 
signaling pathway would activate the downstream apoptosis pathway and promote cell 
apoptosis (Cervellati et al., 2014; Nunomura et al., 2001). Accumulation of Aβ, which 
induces cytotoxicity and behavior impairments, may lead to a decrease of the level of Akt 
and of MEK1/2 activity (Kashour et al., 2003; Ryder et al., 2004). Our experiment shows 
that lixisenatide prevents the Aβ25-35 induced decrease of pAkt and pMEK1/2 levels, 
indicating that activation of the Akt-MEK1/2 signaling pathway might be involved in the 
protective action of lixisenatide against Aβ toxicity. 
    A number of studies have shown that perturbed cellular Ca2+ homeostasis may play a 
prominent role in neuronal death in AD (LaFerla, 2002). The elevation of intracellular 
calcium mediated the neurotoxicity induced by Aβ in primary cortical neurons (Fu et al., 
2006) and hippocampal neurons (Kelly and Ferreira, 2006). In this study, we observed the 
effect of Aβ25-35 on the intracellular Ca2+ level in cultured primary rat hippocampal 
neurons. Our results showed that Aβ25-35 significantly increased the intracellular Ca2+ 
level, while lixisenatide pretreatment effectively suppressed Aβ25-35-induced Ca2+ 
elevation, demonstrating the association between Aβ and intracellular calcium overload, and 
suggesting the protection of lixisenatide might be due to alleviating Aβ-induced 
intracellular calcium overload. We further explored the effect of U0126 (a specific MEK1/2 
inhibitor, with the cell permeability) in the lixisenatide plus Aβ25-35 group. Our results 
indicate that the effect of lixisenatide on calcium homeostasis was mostly blocked in the 
presence of U0126, which might suggest that the MEK1/2 signaling pathway is involved in 
Lixisenatide is neuroprotective 
	
	 13	
the process of calcium homeostasis. This result confirms our previous cell culture study that 
demonstrates a normalizing effect of liraglutide in SH-SY5Y cells via activating Akt and 
MEK1/2 (Sharma et al., 2013). Furthermore, the observed effects explain in part the 
Neuroprotective effects of lixisenatide in the APP/PS1 mouse model of AD that we have 
found previously (McClean and Holscher, 2014). 
    In summary, the present study confirmed the previous reports of the neuroprotective 
and cytoprotective action of lixisenatide against Aβ, suggesting that the protection of 
lixisenatide may be involved in the activation of Akt-MEK1/2 signaling pathway and the 
regulation of intracellular calcium homeostasis. 




Figure 1. Lixisenatide alleviated the detrimental effect induced by Aβ25-35 in Y maze 
working memory test.  
A, histograms showing the lower spontaneous alternation of rats after injection of Aβ25-35 
(***p<0.001, n=10) and a significant recovery in Aβ25-35 plus lixisenatide group 
(***p<0.001, n=10). B, histograms showing no significant difference in total arm entries 
among different groups. 
 
Figure 2. Lixisenatide inhibited the toxicity of Aβ25-35 on cultured hippocampal 
neurons.  
Cells were incubated with Aβ25–35 (10 µM) in the absence or presence of lixisenatide (100 
µM) for 24 h. The cell viability and cytotoxicity were tested with CCK-8 and LDH assay, 
respectively. A, Histograms showing the lower viability of cultured hippocampal neurons in 
Aβ25-35 plus vehicle group (n=10) and a significant reverse in Aβ25-35 plus lixisenatide 
group (n=10). B, Histograms showing the higher toxicity in Aβ25-35 plus vehicle group 
(n=10) and a significant recovery in Aβ25-35 plus lixisenatide group (n=10). ***p<0.001 
 
Figure 3. Lixisenatide prevented Aβ25-35 induced down regulation of pAKT and 
pMEK1/2.  
A, histograms showing the lower level of pAKT in Aβ25-35 plus vehicle group (n=10) and 
a significant restoration in Aβ25-35 plus lixisenatide group (n=10). B, histograms showing 
the decreased level of pMEK1/2 in Aβ25-35 plus vehicle group (n=10) and a significant 
reverse in Aβ25-35 plus lixisenatide group (n=10). *p<0.05 
 
Figure 4. Lixisenatide protected against Aβ25-35-induced [Ca2+]i elevation, which was 
abolished by U0126.  
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A, Representative fluorescent [Ca2+]i imaging of cultured hippocampal neurons a, before 
Aβ25-35 injection; b, 20 min after Aβ25-35 injection. Scale length: 20 µm. B, Plots 
showing representative fluorescent intensity traces in different groups. C, histograms 
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